Volume: 45 Issue: 3
Review on chemistry, pharmacology, toxicity and future prospectives of withaferin A
Year: 2023, Page: 108-122, Doi: https://doi.org/10.62029/jmaps.v45i3.shukla
Received: Dec. 7, 2023 Accepted: Dec. 19, 2023 Published: Dec. 31, 2023
The medicinal plant Withania somnifera is widely researched for its antiinflammatory, cardioprotective, and anticancer effects. W. somnifera preparations are specifically used to treat menstruation issues and arthritis in Ayurveda, the main traditional Indian medical system. The bioactive substance withaferin A (WA), a steroidal lactone, was first isolated from the leaves of W. somnifera. Numerous studies showed that WA contains various pharmacological properties, making it a good choice for treating various diseases. Its structural modification targets several signal transduction pathways and improves the effectiveness of treatment for a range of illnesses. We comprehensively reviewed withaferin A and its pharmacological activities against various diseases. Among the most well-studied effects of withaferin A are anticancer properties, including breast cancer, ovarian cancer, prostate cancer, lung cancer, colorectal cancer, multiple myeloma, neuroblastoma, leukaemia, and glioblastoma, where WA have shown the potential anticancer effect. The studies demonstrated that WA inhibits the growth and metastasis of several cancer cell lines. The current review thoroughly analyses the pharmacokinetics, biological activities, and changes of several disease targets linked to WA.
Keywords: Biosynthesis, Pharmacology, Toxicity, Withaferin A, Withania somnifera
Agarwalla, P., Mukherjee, S., Sreedhar, B., & Banerjee, R. (2016). Glucocorticoid receptor-mediated delivery of nano gold–withaferin conjugates for reversal of epithelial-to-mesenchymal transition and tumor regression. Nanomedicine (London), 11, 2529–2546.
Aminu, N., Bello, I., Umar, N. M., Tanko, N., Aminu, A., & Audu, M. M. (2020). The influence of nanoparticulate drug delivery systems in drug therapy. Journal of Drug Delivery Science and Technology, 60, 101961.
Atluri, V. S. R., Tiwari, S., Rodriguez, M., Kaushik, A., Yndart, A., Kolishetti, N., & Nair, M. (2020). Inhibition of amyloid-beta production, associated neuroinflammation, and histone deacetylase 2-mediated epigenetic modifications prevent neuropathology in Alzheimer’s disease in vitro model. Frontiers in Aging Neuroscience, 11, 342.
Atteeq, M. (2022). Evaluating anticancer properties of Withaferin A: A potent phytochemical. Frontiers in Pharmacology, 13, 975320.
Bargagna-Mohan, P., Hamza, A., Kim, Y.-e., Ho, Y. K. A., Mor-Vaknin, N., Wendschlag, N., & Zhan, C.-G. (2007). The tumor inhibitor and antiangiogenic agent withaferin A targets the intermediate filament protein vimentin. Chemistry & Biology, 14, 623–634.
Bartkova, J., Höřejší, Z., Koed, K., Krämer, A., Tort, F., Zieger, K., & Lukas, C. (2005). DNA damage response as a candidate anticancer barrier in early human tumorigenesis. Nature, 434, 864–870.
Berghe, W. V., Sabbe, L., Kaileh, M., Haegeman, G., & Heyninck, K. (2012). Molecular insight into the multifunctional activities of withaferin A. Biochemical Pharmacology, 84, 1282–1291.
Bhat, W. W., Lattoo, S. K., Razdan, S., Dhar, N., Rana, S., Dhar, R. S., & Vishwakarma, R. A. (2012). Molecular cloning, bacterial expression, and promoter analysis of squalene synthase from Withania somnifera (L.) Dunal. Gene, 499, 25–36.
Deocaris, C. C., Lu, W.-J., Kaul, S. C., & Wadhwa, R. (2013). Druggability of mortalin for cancer and neurodegenerative disorders. Current Pharmaceutical Design, 19, 418–429.
Cereda, V., Formica, V., Massimiani, G., Tosetto, L., & Roselli, M. (2014). Targeting metastatic castration-resistant prostate cancer: Mechanisms of progression and novel early therapeutic approaches. Expert Opinion on Investigational Drugs, 23, 469–487.
Chakraborty, S., Mallick, D., Goswami, M., Guengerich, F. P., Chakrabarty, A., & Chowdhury, G. (2022). The natural products withaferin A and withanone from the medicinal herb Withania somnifera are covalent inhibitors of the SARS-CoV-2 main protease. Journal of Natural Products, 85, 2340–2350.
Chatterjee, S., Srivastava, S., Khalid, A., Singh, N., Sangwan, R. S., Sidhu, O. P., & Tuli, R. (2010). Comprehensive metabolic fingerprinting of Withania somnifera leaf and root extracts. Phytochemistry, 71, 1085–1094.
Chaudhary, A., Kalra, R. S., Malik, V., Katiyar, S. P., Sundar, D., Kaul, S. C., & Wadhwa, R. (2019). 2,3-dihydro-3′-methoxy withaferin A lacks anti-metastasis potency: Bioinformatics and experimental evidence. Scientific Reports, 9, 17344.
Choudhary, M. I., Yousuf, S., Nawaz, S. A., & Ahmed, S. (2004). Cholinesterase inhibiting withanolides from Withania somnifera. Chemical and Pharmaceutical Bulletin, 52, 1358–1361.
Dai, T., Jiang, W., Guo, Z., Wang, Z., Huang, M., Zhong, G., & Dai, R. (2019). Studies on oral bioavailability and first-pass metabolism of withaferin A in rats using LC–MS/MS and Q-TRAP. Biomedical Chromatography, 33, e4573.
Das, T., Roy, K. S., Chakrabarti, T., Mukhopadhyay, S., & Roychoudhury, S. (2014). Withaferin A modulates the spindle assembly checkpoint by degradation of Mad2–Cdc20 complex in colorectal cancer cell lines. Biochemical Pharmacology, 91, 31–39.
Devkar, S. T., Kandhare, A. D., Sloley, B. D., Jagtap, S. D., Lin, J., Tam, Y. K., & Hegde, M. V. (2015). Evaluation of the bioavailability of major withanolides of Withania somnifera using an in vitro absorption model system. Journal of Advanced Pharmaceutical Technology & Research, 6, 159.
Ferlay, J., Shin, H. R., Bray, F., Forman, D., Mathers, C., & Parkin, D. M. (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. International Journal of Cancer, 127, 2893–2917.
Fong, M. Y., Jin, S., Rane, M., Singh, R. K., Gupta, R., & Kakar, S. S. (2012). Withaferin A synergizes the therapeutic effect of doxorubicin through ROS-mediated autophagy in ovarian cancer. PLOS ONE, 7, e30698.
Friedman, S. L., Neuschwander-Tetri, B. A., Rinella, M., & Sanyal, A. J. (2018). Mechanisms of NAFLD development and therapeutic strategies. Nature Medicine, 24, 908–922.
Fuska, J., Fuskova, A., Rosazza, J., & Nicholas, A. (1984). Novel cytotoxic and antitumor agents. IV. Withaferin A: Relation of its structure to the in vitro cytotoxic effects on P388 cells. Neoplasma, 31, 31–36.
Grin, B., Mahammad, S., Wedig, T., Cleland, M. M., Tsai, L., Herrmann, H., & Goldman, R. D. (2012). Withaferin A alters intermediate filament organization, cell shape, and behavior. PLOS ONE, 7, e39065.
Guo, R., Gan, L., Lau, W. B., Yan, Z., Xie, D., Gao, E., & Wang, Y. (2019). Withaferin A prevents myocardial ischemia/reperfusion injury by upregulating AMP-activated protein kinase-dependent B-cell lymphoma 2 signaling. Circulation Journal, 83, 1726–1736.
Gupta, R. C., Bansal, S. S., Aqil, F., Jeyabalan, J., Cao, P., Kausar, H., & Vadhanam, M. V. (2012). A controlled-release systemic delivery new concept in cancer chemoprevention. Carcinogenesis, 33, 1608–1615.
Hahm, E.-R., Moura, M. B., Kelley, E. E., Van Houten, B., Shiva, S., & Singh, S. V. (2011). Withaferin A-induced apoptosis in human breast cancer cells is mediated by reactive oxygen species. PLOS ONE, 6, e23354.
Hassannia, B., Wiernicki, B., Ingold, I., Qu, F., Van Herck, S., Tyurina, Y. Y., & Choi, S. M. (2018). Nano-targeted induction of dual ferroptotic mechanisms eradicates high-risk neuroblastoma. The Journal of Clinical Investigation, 128, 3341–3355.
Heneka, M. T., Kummer, M. P., Stutz, A., Delekate, A., Schwartz, S., Vieira-Saecker, A. M., & Tzeng, T.-C. (2013). NLRP3 is activated in Alzheimer’s disease and contributes to pathology in APP/PS1 mice. Nature, 493, 674–678.
Huang, C., Vaishnavi, K., Kalra, R., Zhang, Z., Sekar, K., Kaul, S. C., & Wadhwa, R. (2015). 3β-methoxy derivation of withaferin A attenuates its anticancer potency: Bioinformatics and molecular evidence. Medicinal Aromatic Plants, 4, 100021.
Johny, L., Conlan, X., Cahill, D., & Adholeya, A. (2015). In vitro and in situ screening systems for morphological and phytochemical analysis of Withania somnifera germplasms. Plant Cell, Tissue and Organ Culture, 120, 1191–1202.
Kabir, M. T., Uddin, M. S., Jeandet, P., Emran, T. B., Mitra, S., Albadrani, G. M., & Simal-Gandara, J. (2021). Antialzheimer’s molecules derived from marine life: Understanding molecular mechanisms and therapeutic potential. Marine Drugs, 19, 251.
Kakar, S. S., Parte, S., Carter, K., Joshua, I. G., Worth, C., Rameshwar, P., & Ratajczak, M. Z. (2017). Withaferin A (WFA) inhibits tumor growth and metastasis by targeting ovarian cancer stem cells. Oncotarget, 8, 74494.
Kelm, N. Q., Straughn, A. R., & Kakar, S. S. (2020). Withaferin A attenuates ovarian cancer-induced cardiac cachexia. PLOS ONE, 15, e0236680.
Khalilpourfarshbafi, M., Devi Murugan, D., Abdul Sattar, M. Z., Sucedaram, Y., & Abdullah, N. A. (2019). Withaferin A inhibits adipogenesis in the 3T3-F442A cell line, improves insulin sensitivity, and promotes weight loss in high-fat diet-induced obese mice. PLOS ONE, 14, e0218792.
Khedgikar, V., Kushwaha, P., Gautam, J., Verma, A., Changkija, B., Kumar, A., & Trivedi, P. (2013). Withaferin A: A proteasomal inhibitor that promotes healing after injury and exerts an anabolic effect on osteoporotic bone. Cell Death & Disease, 4, e778.
Kim, S.-H., Hahm, E.-R., Singh, K. B., Shiva, S., Stewart-Ornstein, J., & Singh, S. V. (2020). RNA-seq reveals novel mechanistic targets of withaferin A in prostate cancer cells. Carcinogenesis, 41, 778–789.
Kreso, A., & Dick, J. E. (2014). Evolution of the cancer stem cell model. Cell Stem Cell, 14, 275–291.
Kyakulaga, A. H., Aqil, F., Munagala, R., & Gupta, R. C. (2018). Withaferin A inhibits epithelial to mesenchymal transition in non-small cell lung cancer cells. Scientific Reports, 8, 15737.
Lee, J., Hahm, E. R., & Singh, S. V. (2010). Withaferin A inhibits the activation of signal transducer and activator of transcription 3 in human breast cancer cells. Carcinogenesis, 31, 1991–1998.
Li, X., Zhu, F., Jiang, J., Sun, C., Wang, X., Shen, M., & Peng, F. (2015). Synergistic antitumor activity of withaferin A combined with oxaliplatin triggers reactive oxygen species-mediated inactivation of the PI3K/AKT pathway in human pancreatic cancer cells. Cancer Letters, 357, 219–230.
Liu, W., Wang, G., Palovcak, A., Li, Y., Hao, S., Liu, Z. J., & Zhang, Y. (2019). Impeding the single-strand annealing pathway of DNA double-strand break repair by withaferin A-mediated FANCA degradation. DNA Repair, 77, 10–17.
Lombardi, R., Betocchi, S., Losi, M. A., Tocchetti, C. G., Aversa, M., Miranda, M., & Chiariello, M. (2003). Myocardial collagen turnover in hypertrophic cardiomyopathy. Circulation, 108, 1455–1460.
Luo, Y., Cui, X., Zhao, J., Han, Y., Li, M., Lin, Y., & Lan, L. (2014). Cells susceptible to epithelial-mesenchymal transition are enriched in stem-like side population cells from prostate cancer. Oncology Reports, 31, 874–884.
Meena, A. K., Rekha, P., Perumal, A., Gokul, M., Swathi, K., & Ilavarasan, R. (2021). Estimation of Withaferin-A by HPLC and standardization of the Ashwagandha lehyam formulation. Heliyon, 7.
Michelotti, G. A., Machado, M. V., & Diehl, A. M. (2013). NAFLD, NASH, and liver cancer. Nature Reviews Gastroenterology & Hepatology, 10, 656–665.
Mirjalili, M. H., Moyano, E., Bonfill, M., Cusido, R. M., & Palazón, J. (2009). Steroidal lactones from Withania somnifera, an ancient plant for novel medicine. Molecules, 14, 2373–2393.
Moncrief, J. W., & Heller, K. S. (1967). Acylation: A proposed mechanism of action for various oncolytic agents based on model chemical systems. Cancer Research, 27, 1500–1502.
Moselhy, J., Suman, S., Alghamdi, M., Chandarasekharan, B., Das, T. P., Houda, A., & Damodaran, C. (2017). Withaferin A inhibits prostate carcinogenesis in a PTEN-deficient mouse model of prostate cancer. Neoplasia, 19, 451–459.
Narayan, M., Zhang, J., Braswell, K., Gibson, C., Zitnyar, A. C., Lee, D. K., & Jinwal, U. (2015). Withaferin A regulates LRRK2 levels by interfering with the Hsp90-Cdc37 chaperone complex. Current Aging Science, 8, 259–265.
O'Regan, R. M., & Jordan, V. C. (2002). The evolution of tamoxifen therapy in breast cancer: Selective estrogen-receptor modulators and downregulators. The Lancet Oncology, 3, 207–214.
Pal, D., Tyagi, A., Chandrasekaran, B., Alattasi, H., Ankem, M. K., Sharma, A. K., & Damodaran, C. (2018). Suppression of Notch1 and AKT mediated epithelial to mesenchymal transition by Verrucarin J in metastatic colon cancer. Cell Death & Disease, 9, 798.
Patel, D. P., Yan, T., Kim, D., Dias, H. B., Krausz, K. W., Kimura, S., & Gonzalez, F. J. (2019). Withaferin A improves non-alcoholic steatohepatitis in mice. Journal of Pharmacology and Experimental Therapeutics, 371, 360–374.
Patel, S. B., Rao, N. J., & Hingorani, L. L. (2016). Safety assessment of Withania somnifera extract standardized for Withaferin A: Acute and sub-acute toxicity study. Journal of Ayurveda and Integrative Medicine, 7, 30–37.
Patil, D., Gautam, M., Mishra, S., Karupothula, S., Gairola, S., Jadhav, S., & Patwardhan, B. (2013). Determination of withaferin A and withanolide A in mice plasma using high-performance liquid chromatography-tandem mass spectrometry: Application to pharmacokinetics after oral administration of Withania somnifera aqueous extract. Journal of Pharmaceutical and Biomedical Analysis, 80, 203–212.
Pires, N., Gota, V., Gulia, A., Hingorani, L., Agarwal, M., & Puri, A. (2020). Safety and pharmacokinetics of Withaferin-A in advanced stage high-grade osteosarcoma: A phase I trial. Journal of Ayurveda and Integrative Medicine, 11, 68–72.
Prabu, P., Panchapakesan, S., & Raj, C. D. (2013). Acute and sub‐acute oral toxicity assessment of the hydroalcoholic extract of Withania somnifera roots in Wistar rats. Phytotherapy Research, 27, 1169–1178.
Rabhi, C., Arcile, G., Le Goff, G., Da Costa Noble, C., & Ouazzani, J. (2019). Neuroprotective effect of CR-777, a glutathione derivative of Withaferin A, obtained through the bioconversion of Withania somnifera (L.) Dunal extract by the fungus Beauveria bassiana. Molecules, 24, 4599.
Raziya Banu, M., Ibrahim, M., Prabhu, K., & Rajasankar, S. (2020). Withaferin-A protects the nigral dopamine neuron and recovers motor activity in aged rats. Cells Tissues Organs, 208, 59–65.
Riboulet-Chavey, A., Diraison, F., Siew, L. K., Wong, F. S., & Rutter, G. A. (2008). Inhibition of AMP-activated protein kinase protects pancreatic β-cells from cytokine-mediated apoptosis and CD8+ T-cell–induced cytotoxicity. Diabetes, 57, 415–423.
Rona, G. (1985). Catecholamine cardiotoxicity. Journal of Molecular and Cellular Cardiology, 17, 291–306.
Santagata, S., Xu, Y. M., Wijeratne, E. K., Kontnik, R., Rooney, C., Perley, C. C., & Whitesell, L. (2012). Using the heat-shock response to discover anticancer compounds that target protein homeostasis. ACS Chemical Biology, 7, 340–349.
Shah, H. S., Usman, F., Ashfaq-Khan, M., Khalil, R., Ul-Haq, Z., Mushtaq, A., & Iqbal, J. (2020). Preparation and characterization of anticancer liposomal withaferin-A formulation for improved delivery to cancer cells: In vitro, in vivo, and silico evaluation. Journal of Drug Delivery Science and Technology, 59, 101863.
Singh, S., Pal, S., Shanker, K., Chanotiya, C. S., Gupta, M. M., Dwivedi, U. N., & Shasany, A. K. (2014). Sterol partitioning by HMGR and DXR for routing intermediates toward withanolide biosynthesis. Physiologia Plantarum, 152, 617–633.
Sivasankarapillai, V. S., Madhu Kumar Nair, R., Rahdar, A., Bungau, S., Zaha, D. C., Aleya, L., & Tit, D. M. (2020). Overview of the anticancer activity of withaferin A, an active constituent of the Indian ginseng Withania somnifera. Environmental Science and Pollution Research, 27, 26025–26035.
Shohat, B., Gitter, E., Abraham, A., & Lavie, D. (1967). Antitumor activity of withaferin A. Cancer Chemotherapy Reports, 51, 271–276.
Stan, S. D., Zeng, Y., & Singh, S. V. (2008). Ayurvedic medicine constituent withaferin A causes G2 and M phase cell cycle arrest in human breast cancer cells. Nutrition and Cancer, 60, 51–60.
Straughn, A. R., & Kakar, S. S. (2019). Withaferin A ameliorates ovarian cancer-induced cachexia and proinflammatory signaling. Journal of Ovarian Research, 12, 1–14.
Sultana, F., Neog, M. K., & Rasool, M. (2017). Withaferin-A, a steroidal lactone encapsulated mannose decorated liposomes ameliorates rheumatoid arthritis by intriguing the macrophage repolarization in adjuvant-induced arthritic rats. Colloids and Surfaces B: Biointerfaces, 155, 349–365.
Suman, S., Das, T. P., Moselhy, J., Pal, D., Kolluru, V., Alatassi, H., & Damodaran, C. (2016). Oral administration of withaferin A inhibits carcinogenesis of the prostate in the TRAMP model. Oncotarget, 7, 53751–53761.
Tekula, S., Khurana, A., Anchi, P., & Godugu, C. (2018). Withaferin-A attenuates multiple low doses of streptozotocin (MLD-STZ) induced type 1 diabetes. Biomedicine & Pharmacotherapy, 106, 1428–1440.
Thirugnanasambantham, P., Roy, I. M., Charles, S. N., & Senthil, K. (2014). Ontogenetic assessment of withanolide biogenesis and expression of selected pathway genes in Withania somnifera, a traditional medicinal herb. Journal of Pharmacy Research, 8, 1344–1351.
Tit, D. M., Bungau, S., Iovan, C., Nistor Cseppento, D. C., Endres, L., Sava, C., & Furau, C. (2018). Effects of the hormone replacement therapy and soy isoflavones on bone resorption in postmenopause. Journal of Clinical Medicine, 7, 297.
Tiwari, S., Atluri, V. S. R., Yndart Arias, A., Jayant, R. D., Kaushik, A., Geiger, J., & Nair, M. N. (2018). Withaferin A suppresses beta-amyloid in APP expressing cells: Studies for tat and cocaine-associated neurological dysfunctions. Frontiers in Aging Neuroscience, 10, 291.
Vesa, C. M., Popa, L., Popa, A. R., Rus, M., Zaha, A. A., Bungau, S., & Zaha, D. C. (2020). Current data regarding the relationship between type 2 diabetes mellitus and cardiovascular risk factors. Diagnostics, 10, 314.
Walle, T. (2009). Methylation of dietary flavones increases their metabolic stability and chemopreventive effects. International Journal of Molecular Sciences, 10, 5002–5019.
Xu, K., Shi, H., Du, Y., & Ou, J. (2021). Withaferin A inhibits the proliferation of human endometrial cancer cells via transforming growth factor-β (TGF-β) signaling. Biotech, 11, 323.
Yokota, Y., Bargagna-Mohan, P., Ravindranath, P. P., Kim, K. B., & Mohan, R. (2006). Development of withaferin A analogs as probes of angiogenesis. Bioorganic & Medicinal Chemistry Letters, 16, 2603–2607.
Yousefian, Z., Hosseini, B., Rezadoost, H., Palazón, J., & Mirjalili, M. H. (2018). Production of the anticancer compound withaferin from genetically transformed hairy root cultures of Withania somnifera. Natural Product Communications, 13, 943–948.
Yousuf, S. K., Majeed, R., Ahmad, M., Lal Sangwan, P., Purnima, B., Saxena, A., & Taneja, S. C. (2011). Ring A structurally modified derivatives of withaferin A and the evaluation of their cytotoxic potential. Steroids, 76, 1213–1222.
Zhang, X., Samadi, A. K., Roby, K. F., Timmermann, B., & Cohen, M. S. (2012). Inhibition of cell growth and induction of apoptosis in ovarian carcinoma cell lines CaOV3 and SKOV3 by natural withanolide Withaferin A. Gynecologic Oncology, 124, 606–612.
Zomborszki, Z. P., Peschel, W., Boros, K., Hohmann, J., & Csupor, D. (2016). Development of an optimized processing method for Withania frutescens. Acta Alimentaria, 45, 452–456.
© CSIR-Central Institute of Medicinal and Aromatic Plants, Lucknow-226015
Shukla, A., Srivastava, S., & Dev, K. (2023). Review on chemistry, pharmacology, toxicity and future prospectives of withaferin A. Journal of Medicinal and Aromatic Plant Sciences, 45(3), 108–122.
